2020 ASCO Highlights on Pancreatic Cancer: Perioperative Chemo + mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel for PDAC - Which Option Improves Chemo Delivery and Early Control of Systemic Disease?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

2020 ASCO Highlights on Pancreatic Cancer: Perioperative Chemo + mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel for PDAC - Which Option Improves Chemo Delivery and Early Control of Systemic Disease?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Daniel Catenacci

507 views

September 16, 2020

0 Comments

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi

Explore the mechanism of Action of a TKI in HCC

Feat. W. Keiser

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

Feat. N. Uboha, A. Turk, K. Spencer, M. Cecchini

23:58

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Key Studies

Feat. R. Kim, R. Mehta

03:50

UCLA Health

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

Feat. Z. Wainberg

07:53

Total Health

Updates on Pancreatic Cancer - 2023 ASCO® Direct Philadelphia

Feat. D. Lin

30:55

2023 Johns Hopkins Updates in Gastrointestinal Cancers

Medical Oncology Updates in Pancreas Cancer

Feat. T. Bekaii-Saab

06:28

Shubham Pant

FDA Approval of Liposomal Irinotecan/NALIRIFOX in 1L Metastatic Panc…

17:05

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "A Multicenter, Randomized, Open-Label, Thr…

Feat. A. Ohba

22:10

Yale Cancer Center

Pancreatic Cancer Updates From Yale Cancer Center

Feat. J. Lacy

08:08

Integrity Continuing Education

Updates in Nonmetastatic Upper-GI Adenocarcinoma

Feat. J. Hernandez

25:56

OncoAlert

Year in Review: Pancreatic Cancers

Feat. M. Lewis

10:53

Yale Cancer Center

GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 …

Feat. J. Lacy

18:35

Rachna Shroff

Augmenting Standard Treatment Options in Pancreatic Cancer

15:25

Scripps MD Anderson Cancer Center

Pancreatic Cancer Trials - Evolving Landscape and Treatment Guidance

Feat. J. Hecht

07:42

Integrity Continuing Education

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Feat. W. Burns

06:16

ecancer

ASCO® 2023 Insights: "NAPOLI 3 Analysis of 1L NALIRIFOX vs. Gem…

Feat. E. O’Reilly

10:41

ASCO GI 2023 Conference Coverage

ASCO GI 2023 NAPOLI-3 Randomized, Open-Label Phase 3 Study: Liposoma…

Feat. Z. Wainberg

08:03

Insights from 2023 ESMO World Congress on Gastrointestinal Cancer Annual Meeting

2023 ESMO WCGIC Insights: "Additional Results From the Phase 3 …

Feat. Z. Wainberg

23:32

The University of Kansas Cancer Center

Updates on Pancreatic Cancer Treatment

Feat. A. Kasi

21:43

OncoAlert

OncoAlert Updates on Pancreatic Cancer

Feat. M. Lewis

05:54

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase 3 PANOVA-3 Study - TTF Therapy Conc…

Feat. H. Babiker

Login

Login

Join VuMedi

2020 ASCO Highlights on Pancreatic Cancer: Perioperative Chemo + mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel for PDAC - Which Option Improves Chemo Delivery and Early Control of Systemic Disease?

Related Content